Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
UCSF - oral vancomycin for C. difficile
Product / population
Adults; oral vancomycin for C. difficile only.
Renal method
Qualitative no renal reduction for these oral regimens.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
UCSF Infectious Diseases Management Program · Adults; oral vancomycin for C. difficile only.
Renal method: Qualitative no renal reduction for these oral regimens. Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
Initial non-fulminant C. difficile infection: 125 mg orally four times daily. Fulminant disease: 500 mg four times daily under the full severe-CDI pathway; rectal administration may also be considered. The source does not reduce these oral doses for kidney dysfunction or HD.
Oral vancomycin is not a substitute for IV therapy of systemic infection. Taper schedules and additional fulminant-disease treatments require the complete CDI guideline.
RDM30-058-vancomycin-oral-1 · Source locator: UCSF - oral vancomycin for C. difficile; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.